Year None20222021202020192018201720162015201420132012 09.02.2020 Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 09.01.2020 Iveric Bio Announces Publication of GATHER1 Phase 3 Clinical Trial Results for Zimura® in Geographic Atrophy Secondary to Age-related Macular Degeneration, in Ophthalmology®, the Journal of the American Academy of Ophthalmology 08.05.2020 Iveric Bio Reports Second Quarter 2020 Operational Highlights and Financial Results 08.04.2020 Iveric Bio to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference 08.03.2020 Iveric Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) 07.29.2020 Iveric Bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Wednesday, August 5, 2020 07.16.2020 Iveric Bio Announces the Addition of Mark S. Blumenkranz, M.D., M.M.S., to its Board of Directors 06.30.2020 Iveric Bio Announces First Patient Dosed in Second Zimura® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration 06.22.2020 Iveric Bio Announces Closing of Public Offering and Concurrent Private Placement with $160 Million in Gross Proceeds 06.18.2020 Iveric Bio Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Pagination First page « first Previous page ‹ previous … Page 3 Page 4 Page 5 Page 6 Current page 7 Page 8 Page 9 Page 10 Page 11 … Next page next › Last page last »